ATNF vs. PRFX, ALLR, INM, QLGN, PXMD, NBSE, CMND, BPTH, GLMD, and LSDI
Should you be buying 180 Life Sciences stock or one of its competitors? The main competitors of 180 Life Sciences include PainReform (PRFX), Allarity Therapeutics (ALLR), InMed Pharmaceuticals (INM), Qualigen Therapeutics (QLGN), PaxMedica (PXMD), NeuBase Therapeutics (NBSE), Clearmind Medicine (CMND), Bio-Path (BPTH), Galmed Pharmaceuticals (GLMD), and Lucy Scientific Discovery (LSDI). These companies are all part of the "pharmaceutical preparations" industry.
PainReform (NASDAQ:PRFX) and 180 Life Sciences (NASDAQ:ATNF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking.
PainReform and 180 Life Sciences both received 2 outperform votes by MarketBeat users. However, 100.00% of users gave PainReform an outperform vote while only 66.67% of users gave 180 Life Sciences an outperform vote.
180 Life Sciences' return on equity of 0.00% beat PainReform's return on equity.
37.3% of PainReform shares are held by institutional investors. Comparatively, 4.1% of 180 Life Sciences shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Comparatively, 4.1% of 180 Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, PainReform and PainReform both had 3 articles in the media. 180 Life Sciences' average media sentiment score of 0.96 beat PainReform's score of 0.91 indicating that PainReform is being referred to more favorably in the media.
PainReform has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, 180 Life Sciences has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.
Summary
PainReform beats 180 Life Sciences on 8 of the 8 factors compared between the two stocks.
Get 180 Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATNF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
180 Life Sciences Competitors List
Related Companies and Tools
